Cerises 🇨🇵

Long COVID Research: A Disappointing Past and a Promising Future To date, much of #LongCOVID research has remained observational, with comparatively limited investment in mechanistic pathobiology and rigorously powered interventional trials. At the same time, the patient community has consistently put forward clear, thoughtful research priorities—yet we continue to see repetition of efforts, limited innovation, and missed opportunities to move the field forward in a meaningful way. In collaboration with the University of California, Irvine, #TechImmune has identified a specific immune dysfunction in Long COVID patients that may contribute to persistent viral reservoirs. They are advancing a novel, first-in-class antiviral immunotherapy designed to correct this defect and enable viral clearance, with clinical trials anticipated to begin this year. This type of mechanistic, targeted, and innovative research—focused on underlying disease drivers rather than symptom management—is exactly what we need to see more of across the field. In recognition of #LongCOVIDAwareness Month and in support of patients, TechImmune has issued the following statement which you can read here along with #C19LAP’s research priorities: bit.ly/LCAMTIS

This week in illogical clinical trials: RECOVER-VITAL shows no benefit for long COVID with 15-day or 25-day paxlovid. Results appeared in the registry 15 months after primary completion, with no publication or announcement. c19early.org/zimmerman2.html Four trials have tested paxlovid for long COVID treatment: three show no benefit and one remains unreported. While authors did not publish the results, they published a paper this month that states: “While the STOP-PASC and PAX LC trials did not demonstrate a positive effect on Long COVID, the RECOVER-VITAL study remains a critical addition to the field and still has potential for demonstrating effect…” journals.sagepub.com/doi/10.1177/17… 🧵

Another Long COVID clinical trial bites the dust. I know from clinical experience that Ivabradine does have benefit in a certain group of patients. But typical for most of these trials. They enrolled the wrong cohort of patients. Rinse and repeat until all the funding is gone? recovercovid.org/news/recover-a…

Of all the things after years of connecting with other patients ivabradine was the ONLY thing I can say looked like it was helping folks with #LongCovid POTS. But the trial ivabradine NIH RECOVER AUTONOMIC trial failed - why? 👇🏻👇🏻👇🏻